Industry Roundup: Cardinal Buys Harvard Drug, Similac Lawsuit, State AGs Question Supplement Oversight
This article was originally published in The Tan Sheet
Cardinal acquires Harvard Drug; Similac ‘organic’ claims deceptive – complaint; N.Y., Ind. criticize supplement regulatory flexibility; Amway headquarters manufacturing site opens; and more news in brief.
You may also be interested in...
Watson Pharmaceuticals sells OTC business Rugby Laboratories to Harvard Drug Group, which operates Major Pharmaceuticals manufacturing. Watson divests a business that accounted for a small part of the private label OTC market, but keeps its pending ANDAs for guaifenesin expectorants and its smoking-cessation generics.
The late-breaking clinical trial presentations at this year’s Transcatheter Cardiovascular Therapeutics conference in Boston included new results from trials of three different minimally invasive approaches to treat uncontrolled hypertension.